Across TCGA pan-cancer cohorts, KIR2DL4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KIR2DL4 data layer compared with 30 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KIR2DL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KIR2DL4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and SKCM are the cancer types where KIR2DL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.011	0.784	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.438	.015	20	view →
SKCM	OS	Median	III,IV	0.296	0.737	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KIR2DL4 tumor-vs-normal RNA expression · all KIR2DL4 data types